Current problems in cardiology

Publisher: Elsevier

Journal description

Current impact factor: 2.17

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.167
2012 Impact Factor 2.542
2011 Impact Factor 2.583
2010 Impact Factor 3.435
2009 Impact Factor 3.957
2008 Impact Factor 3.292
2006 Impact Factor 3.417
2005 Impact Factor 3.6
2004 Impact Factor 0.867
2003 Impact Factor 0.917
2002 Impact Factor 1.042
2001 Impact Factor 1.042
2000 Impact Factor 1.5
1999 Impact Factor 1.125
1998 Impact Factor 1.609
1997 Impact Factor 0.913
1996 Impact Factor 1
1995 Impact Factor 2.25
1994 Impact Factor 1.292
1993 Impact Factor 1.125
1992 Impact Factor 1.333

Impact factor over time

Impact factor
Year

Additional details

5-year impact 4.07
Cited half-life 5.00
Immediacy index 0.67
Eigenfactor 0.00
Article influence 1.25
Other titles Current problems in cardiology (Online), Current problems in cardiology
ISSN 1535-6280
OCLC 47143582
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Elsevier

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Pre-print allowed on any website or open access repository
    • Voluntary deposit by author of authors post-print allowed on authors' personal website, arXiv.org or institutions open scholarly website including Institutional Repository, without embargo, where there is not a policy or mandate
    • Deposit due to Funding Body, Institutional and Governmental policy or mandate only allowed where separate agreement between repository and the publisher exists.
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months .
    • Set statement to accompany deposit
    • Published source must be acknowledged
    • Must link to journal home page or articles' DOI
    • Publisher's version/PDF cannot be used
    • Articles in some journals can be made Open Access on payment of additional charge
    • NIH Authors articles will be submitted to PubMed Central after 12 months
    • Publisher last contacted on 18/10/2013
  • Classification
    ​ green

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: An escalating body of epidemiologic and clinical research provides compelling evidence that exposure to fine particulate matter air pollution contributes to the development of cardiovascular disease and the triggering of acute cardiac events. There are 3 potential mediating pathways that have been implicated, including "systemic spillover," autonomic imbalance, and circulating particulate matter constituents. Further support that the increased morbidity and mortality attributed to air pollution comes from studies demonstrating the adverse cardiovascular effects of even brief periods of exposure to secondhand smoke. Accordingly, persons with known or suspected cardiovascular disease, the elderly, diabetic patients, pregnant women, and those with pulmonary disease should be counseled to limit leisure-time outdoor activities when air pollution is high. Recognizing the insidious and pervasive nature of air pollution, and the associated odds ratios and population attributable fractions for this widely underappreciated chemical trigger of acute cardiovascular events, may serve to maximize the potential for cardiovascular risk reduction by addressing at least a portion of the 10%-25% incidence of coronary disease that is unexplained by traditional risk factors. Copyright © 2015 Elsevier Inc. All rights reserved.
    Current problems in cardiology 01/2015; 40(5). DOI:10.1016/j.cpcardiol.2015.01.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ischemic strokes will make up most (>80%) of the three-quarters of a million strokes that will occur in Americans this year. Reperfusion therapy is the fundamental strategy for the treatment of acute ischemic stroke. Reperfusion therapy may be accomplished noninvasively (intravenous thrombolysis) or invasively with catheter-based treatments (intra-arterial thrombolysis, thrombectomy, or angioplasty). Currently, a large majority of patients with acute ischemic stroke do not receive any form of reperfusion therapy owing to their delayed presentation (>3 hours) and lack of skilled man power for on-demand endovascular treatment. Paradoxically, improved success rates for reperfusion have been reported with the newer thrombectomy catheters, called "stentreivers." An option for broadening access for patients who need endovascular therapy would be to use interventional cardiologists with carotid stent experience who can help to provide 24×7×365 coverage.
    Current problems in cardiology 03/2014; 39(3):59-76. DOI:10.1016/j.cpcardiol.2013.11.004
  • Article: Foreword.
    Current problems in cardiology 03/2014; 39(3):57. DOI:10.1016/j.cpcardiol.2013.11.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypertension is the leading cause of mortality worldwide. Effective therapies are needed for resistant hypertension, a common condition characterized by inadequate blood pressure control despite 3 or more medications, which is associated with increased cardiovascular mortality. Percutaneous catheter-based renal denervation is a promising new treatment offering the potential to improve blood pressure control, reduce cardiovascular risk, and target end-organ damage in patients with resistant hypertension. Initial studies have demonstrated procedural safety and effectiveness in blood pressure reduction up to 2 years after procedure. Large randomized control trials are necessary and currently underway to define further the role of renal denervation and long-term consequences in the treatment of resistant hypertension.
    Current problems in cardiology 02/2014; 39(2):35-51. DOI:10.1016/j.cpcardiol.2013.11.002
  • Article: Foreword.
    Current problems in cardiology 02/2014; 39(2):33. DOI:10.1016/j.cpcardiol.2013.11.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most surgical heart valves currently implanted are bioprosthetic tissue valves. Such valves deteriorate with time, eventually presenting with either stenosis or regurgitation. Reoperation, the current standard of care for failed valves, carries significant risk in terms of both morbidity and mortality. Implantation of a transcatheter valve inside a failed surgical valve (valve-in-valve procedure) has recently emerged as an alternative, less-invasive option. Although the procedure is similar in some aspects to transcatheter aortic valve implantation in the setting of native aortic valve stenosis, there are many differences that deserve special consideration. We review the potential and challenges of valve-in-valve implantation in patients with failing surgical aortic bioprostheses.
    Current problems in cardiology 01/2014; 39(1):7-27. DOI:10.1016/j.cpcardiol.2013.10.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of cardiovascular diseases (CVDs) in women of childbearing age is rising. The successes in medical and surgical treatment of congenital heart disease have led to an increasing number of women at childbearing age presenting with problems of treated congenital heart disease. Furthermore, in developing countries and in immigrants from these countries, rheumatic valvular heart disease still plays a significant role in young women. Increasing age of pregnant women and increasing prevalence of atherosclerotic risk factors have led to an increase in women with coronary artery disease at pregnancy. Successful management of pregnancy in women with CVDs requires early diagnosis, a thorough risk stratification, and appropriate management by a multidisciplinary team of obstetricians, cardiologists, anesthesiologists, and primary care physicians. The following review is based on the recent European guidelines on the management of CVDs during pregnancy, which aim at providing concise and simple recommendations for these challenging problems.
    Current problems in cardiology 01/2014; 39(4-5):85-151. DOI:10.1016/j.cpcardiol.2014.02.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this article, we explore the clinical and cellular phenomena of primary electrical diseases of the heart, that is, conditions purely related to ion channel dysfunction and not structural heart disease or reversible acquired causes. This growing classification of conditions, once considered together as "idiopathic ventricular fibrillation," continues to evolve and segregate into diseases that are phenotypically, molecularly, and genetically unique.
    Current problems in cardiology 12/2013; 38(12):503-548. DOI:10.1016/j.cpcardiol.2013.07.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Polymorphic ventricular tachycardia (PMVT) is an unusual ventricular tachyarrhythmia. Perhaps its most unique characteristic is a continuously evolving QRS morphology. Although the most common substrate for PMVT is structural heart disease, the prevalence of sudden cardiac death in the population without structural heart disease is even greater, and the absence of a myocardial substrate would suggest that PMVT is the anticipated cause of sudden cardiac death in this population as well. Mechanistically, PMVT is distinct from ventricular fibrillation. It appears to be a condition of abnormal repolarization and resultant cellular heterogeneities, and the principles of triggering and reentry have been demonstrated to govern its initiation and maintenance. The "channelopathies"-a growing category of inherited or acquired conditions that predispose to PMVT and sudden cardiac death-present a fascinating challenge with potentially dire consequences as there are few indicators of their existence except for subtle, if any, electrocardiographic changes. The ever-expanding number of pharmaceuticals that affect ion channel function further magnifies this risk.
    Current problems in cardiology 11/2013; 38(11):463-96. DOI:10.1016/j.cpcardiol.2013.07.001
  • Article: Foreword.
    Current problems in cardiology 10/2013; 38(10):415. DOI:10.1016/j.cpcardiol.2013.06.001
  • Article: Foreword.
    Current problems in cardiology 09/2013; 38(9):363. DOI:10.1016/j.cpcardiol.2013.06.002
  • Article: Foreword.
    Current problems in cardiology 08/2013; 38(8):291. DOI:10.1016/j.cpcardiol.2013.05.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac malformations occur in approximately 1% of live births. Advances in surgery, interventional cardiology, and medical care have translated into increasing numbers of adult patients with congenital heart disease. These patients, even after intervention, have cardiac sequelae that require specialized care by cardiologists and cardiac surgeons with expertise in the management of congenital cardiac disease. We review 8 of the most common lesions encountered after intervention in an adult congenital cardiac practice and discuss longitudinal follow-up, with a focus on appropriate testing, common hemodynamic and electrophysiological issues, and indications for reintervention.
    Current problems in cardiology 08/2013; 38(8):293-357. DOI:10.1016/j.cpcardiol.2013.05.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: In patients with advanced systolic heart failure and mechanical dyssynchrony, cardiac resynchronization therapy (CRT) is an effective means of improving symptoms and reducing mortality. There are now several recognized approaches to optimize CRT. Imaging modalities can assist with identifying the myocardium with the latest mechanical activation for targeted left ventricular lead implantation. Device programming can be tailored to maximize biventricular pacing, and thereby is its benefit. Cardiac imaging has shown that atrioventricular and interventricular intervals can be adjusted to further reduce dyssynchrony. We review these various approaches that maximize the benefit derived from CRT.
    Current problems in cardiology 06/2013; 38(6):215-37. DOI:10.1016/j.cpcardiol.2013.03.003
  • Article: Foreword.
    Current problems in cardiology 06/2013; 38(6):213. DOI:10.1016/j.cpcardiol.2013.03.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerosis of the coronary arteries is common, extensive, and more unstable among patients with chronic renal impairment or chronic kidney disease (CKD). The initial presentation of coronary disease is often acute coronary syndrome (ACS) that tends to be more complicated and has a higher risk of death in this population. Medical treatment of ACS includes antianginal agents, antiplatelet therapy, anticoagulants, and pharmacotherapies that modify the natural history of ventricular remodeling after injury. Revascularization, primarily with percutaneous coronary intervention and stenting, is critical for optimal outcomes in those at moderate and high risk for reinfarction, the development of heart failure, and death in predialysis patients with CKD. The benefit of revascularization in ACS may not extend to those with end-stage renal disease because of competing sources of all-cause mortality. In stable patients with CKD and multivessel coronary artery disease, observational studies have found that bypass surgery is associated with a reduced mortality as compared with percutaneous coronary intervention when patients are followed for several years. This article will review the guidelines-recommended therapeutic armamentarium for the treatment of stable coronary atherosclerosis and ACS and give specific guidance on benefits, hazards, dose adjustments, and caveats concerning patients with baseline CKD.
    Current problems in cardiology 05/2013; 38(5):165-206. DOI:10.1016/j.cpcardiol.2012.12.004
  • Article: Foreword.
    Current problems in cardiology 05/2013; 38(5):163. DOI:10.1016/j.cpcardiol.2012.12.003